Summit Therapeutics (NASDAQ: SMMT) — Perfil da empresa, notícias e dados financeiros
Summit Therapeutics is a biopharmaceutical company focused on novel therapies for infectious diseases.
Summit Therapeutics
Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of targeted medicinal therapies aimed at resolving serious unmet medical needs. The company's primary focus centers on advancing novel bispecific antibody candidates combining anti-PD-1 immunotherapy and anti-VEGF anti-angiogenesis mechanisms. Its key clinical programs target solid tumors, including non-small cell lung cancer, biliary tract cancer, and colorectal cancer across licensed territories including North America, Europe, Japan, Latin America, the Middle East, and Africa. Clinical development includes multiple late-stage Phase III registrational studies evaluating candidate therapies as monotherapy and in combination with chemotherapy or other targeted treatments.
Resumo
Operações
Produtos e/ou serviços de Summit Therapeutics
- Bispecific Monoclonal Antibody Therapy: Development of a novel investigational biopharmaceutical combining programmed cell death protein 1 blockade and vascular endothelial growth factor inhibition into a single molecule to enhance cooperative binding and targeted anti-tumor response in solid tumors.
- EGFR-Mutated Lung Cancer Clinical Program: Execution of Phase III registrational trials evaluating candidate bispecific antibody therapy combined with chemotherapy for patients with advanced or metastatic non-small cell lung cancer following disease progression on epidermal growth factor receptor inhibitors.
- First-Line Non-Small Cell Lung Cancer Program: Multicenter Phase III clinical trials assessing bispecific antibody monotherapy compared against existing standard-of-care immunotherapy regimens in patients presenting with high PD-L1 expression advanced or metastatic non-small cell lung cancer.
- Squamous Lung Cancer Combination Therapy: Late-stage clinical trial program evaluating bispecific antibody administration combined with standard platinum-based chemotherapy against established PD-1 inhibitor regimens in patients with previously untreated metastatic squamous non-small cell lung cancer.
- Gastrointestinal Solid Tumor Development: Phase III clinical trials and pipeline studies expanding antibody candidate evaluation into gastrointestinal cancers, including advanced biliary tract cancer and metastatic colorectal carcinoma, across North American, European, and Asian licensed territories.
- Combination Oncology Clinical Collaborations: Strategic clinical trial partnerships evaluating bispecific antibody candidates in combination with target-directed antibody-drug conjugates and complementary therapeutic agents across multiple advanced solid tumor oncology indications.
equipe executiva do Summit Therapeutics
- Robert W. DugganCo-CEO & Executive Chairman
- Mahkam ZanganehCo-CEO, President & Director
- Manmeet Singh SoniCOO, CFO & Director
- Kay Elizabeth DaviesCo-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
- Bhaskar AnandChief Accounting Officer & Head of Finance
- Nathan LiaBraatenSenior Director of Investor Relations
- Elaine Carla StrackerChief Legal Officer
- Dave GancarzChief Business & Strategy Officer
- Wang Clow Fong ScDChief Biometrics Officer
- Urte GaykoChief Regulatory, Quality & Pharmacovigilance Officer
Últimas notícias sobre a Summit Therapeutics
Summit Therapeutics opens Phase 2 kidney cancer trial
United StatesSummit Therapeutics completes $2 billion AstraZeneca equity investment
United StatesSummit partners with AstraZeneca and Daiichi Sankyo on ivonescimab
United StatesSummit Therapeutics highlights ivonescimab Phase III biliary tract cancer data
United StatesSummit reports ivonescimab trial data
United StatesSummit Therapeutics reports positive lung cancer trial data
United States
Principais indicadores financeiros
Resultados divulgados pela Summit Therapeutics , em GBP.
- Cap. de mercado
- 12,6 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -1,1 bi | -1,1 bi | |
| 0 | -180,5 mi | -176,8 mi | |
| 0 | -478,2 mi | -482,4 mi | |
| 583,2 mil | -59,6 mi | -65,2 mi |